J. Goldman & Co’s Cogent Biosciences COGT Stock Holding History

J. Goldman & Co’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.6M	Buy	+67,600	New	+$2.5M	0.08%	278

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

J. Goldman & Co's COGT Position: Q1 2026 in Review

J. Goldman & Co increased its Cogent Biosciences (COGT) stake by 77% in Q1 2026, buying an estimated $12.6M and bringing the position to 779,570 shares worth $30M. The position accounts for 0.87% of the portfolio, ranked #11.

J. Goldman & Co first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

J. Goldman & Co held 779,570 shares of Cogent Biosciences worth $30M as of Q1 2026.
J. Goldman & Co bought 340,301 Cogent Biosciences shares in Q1 2026, an estimated $12.6M.
Cogent Biosciences made up 0.87% of J. Goldman & Co's portfolio in Q1 2026, its #11 holding.
J. Goldman & Co first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.